BiotechTube

Ofatumumab + Physicians' Choice

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leukaemia

Conditions

Leukaemia

Trial Timeline

Apr 14, 2011 → Apr 24, 2017

NCT ID
NCT01313689

About Ofatumumab + Physicians' Choice

Ofatumumab + Physicians' Choice is a phase 3 stage product being developed by Novartis for Leukaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01313689. Target conditions include Leukaemia.

What happened to similar drugs?

2 of 7 similar drugs in Leukaemia were approved

Approved (2) Terminated (3) Active (2)
✅AcalabrutinibAstraZenecaApproved
✅OfatumumabGenmabApproved
❌chlorambucil, tablets + ofatumumab (GSK1841157) infusionNovartisPhase 3
🔄OFC Infusion + FC infusionNovartisPhase 3
❌NilotinibNovartisPhase 3
❌OfatumumabNovartisPhase 3
🔄Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + CyclophosphamidePfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01313689Phase 3Completed

Competing Products

20 competing products in Leukaemia

See all competitors
ProductCompanyStageHype Score
AZD3632 + PosaconazoleAstraZenecaPhase 1/2
39
AZD1152 + C14 AZD1152AstraZenecaPhase 1
29
AcalabrutinibAstraZenecaApproved
50
AZD2811 + Azacitidine + VenetoclaxAstraZenecaPhase 1
21
Administration of AZD6738AstraZenecaPhase 1
29
AZD1152AstraZenecaPhase 1
29
AZD0486 + Prednisone (or equivalent) + Rituximab + Cyclophosphamide + Vincristine + Doxorubicin + AcalabrutinibAstraZenecaPhase 1/2
39
AZD2171AstraZenecaPhase 1
29
Nilotinib, Pegylated interferon alpha-2b, ImatinibMerckPhase 2
35
chlorambucil, tablets + ofatumumab (GSK1841157) infusionNovartisPhase 3
32
OFC Infusion + FC infusionNovartisPhase 3
40
NilotinibNovartisPhase 3
32
OfatumumabNovartisPhase 3
32
Daunorubicin + Cytarabine + Eltrombopag + PlaceboNovartisPhase 2
35
BlinatumomabAmgenPhase 1
29
Idelalisib + RituximabGilead SciencesPre-clinical
26
humanised monoclonal antibody, veltuzumab + humanised monoclonal antibody epratuzumab + humanised monoclonal antibodies veltuzumab and epratuzumabGilead SciencesPhase 1/2
28
BosulifPfizerPhase 2
31
Bosutinib + Imatinib + Nilotinib + Dasatinib + PonatinibPfizerPre-clinical
26
Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + CyclophosphamidePfizerPhase 3
47